Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > REGULATORY
REGULATORY
- Outline of Expert Panel Report Calls for New Forum to Discuss Generics’ Future, Revisiting of Spillover Rule
April 28, 2023
- Lawmakers’ League on Pollen Allergy Boosts Up
April 27, 2023
- As Japan Mulls Pushing Back Fee Revisions, Chuikyo Reps Fret Impact on Drug Price Updates
April 27, 2023
- Shionogi CEO Presses Govt for G7 Debate on Pull Incentives for Antibiotics
April 27, 2023
- Mpox Cases Hit 120 in Japan: MHLW
April 27, 2023
- Chuikyo OKs CEA Discussion Timeline for FY2024 Reform; Industry Hearing Set for August, November
April 27, 2023
- Ultomiris Clears Japan Panel Review for NMOSD Approval
April 27, 2023
- Japan Panel to Draw Up Revision Outline for Basic Blood Products Policy by September, Eyes Profitability Improvement
April 26, 2023
- Skyrizi in Line for Palmoplantar Pustulosis Nod, Vanflyta for 1st Line AML
April 25, 2023
- Shelf Life for Lagevrio Extended to 36 Months in Japan
April 24, 2023
- MHLW Panel OKs 192 More Health Damage Claims for COVID-19 Vaccines
April 24, 2023
- Japan’s Diet Enacts Bill to Establish Pandemic Response Agency
April 24, 2023
- Health Ministry Panel OKs Japan’s First Abortion Pill with Official Go-Ahead Set for May
April 24, 2023
- Delay Reimbursement Fee Revisions by Few Months: LDP Project Team
April 21, 2023
- Health Minister Negative about Fee Premiums for Use of Japan-Made Drugs
April 20, 2023
- Japan to End Priority Review for COVID Drugs and Vaccines after Severity Downgrade: Official
April 20, 2023
- Industry Groups Call for Reimbursement Scheme Tailored to Characteristics of SaMDs
April 19, 2023
- Push SaMDs from Industrial Policy Viewpoint: Deregulation Panel Member
April 18, 2023
- Wholesaler Lobby Raps Politicians over Product Coverage of Off-Year Cuts
April 18, 2023
- LDP Gathers Steam towards Pharma Policy Proposal Next Month, Sees Honebuto as Make-or-Break Milestone
April 18, 2023
ページ
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…